(MDB) MongoDB - Overview
Stock: Database, Cloud, Enterprise, Community, Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.2% |
| Relative Tail Risk | -20.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | -1.37 |
| Character TTM | |
|---|---|
| Beta | 1.678 |
| Beta Downside | 1.621 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.88% |
| CAGR/Max DD | 0.25 |
Description: MDB MongoDB December 17, 2025
MongoDB, Inc. (NASDAQ:MDB) offers a general-purpose, document-oriented database platform that is delivered through three primary products: MongoDB Atlas (a fully managed, multi-cloud DBaaS), MongoDB Enterprise Advanced (a commercial server for on-premises, cloud, or hybrid deployments), and the free Community Server edition that serves as an entry point for developers. The company also monetizes professional services such as consulting and training.
For fiscal year 2024, MongoDB reported revenue of approximately $1.6 billion, representing a 20% year-over-year increase, and its annual recurring revenue (ARR) grew to about $2.4 billion, reflecting strong customer expansion and higher subscription uptake. Gross margins remained in the low-70% range, consistent with the high-margin nature of software-as-a-service businesses. The firm’s free-tier conversion rate-customers moving from Community Server to paid Atlas subscriptions-stood at roughly 12%, a key lever for future growth.
The database market is being reshaped by accelerating cloud migration, the rise of multi-cloud strategies, and increasing data-intensive workloads from generative AI applications. These macro trends boost demand for flexible, scalable, and developer-friendly platforms like MongoDB, while also intensifying competition from rivals such as Amazon Aurora, Microsoft Azure Cosmos DB, and Snowflake.
For a deeper, data-driven assessment of MDB’s valuation dynamics, consider exploring ValueRay’s analytical toolkit.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -70.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 5.35 > 1.0 |
| NWC/Revenue: 102.5% < 20% (prev 60.20%; Δ 42.27% < -1%) |
| CFO/TA 0.11 > 3% & CFO 384.4m > Net Income -70.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.2m) vs 12m ago 9.76% < -2% |
| Gross Margin: 71.62% > 18% (prev 0.74%; Δ 7088 % > 0.5%) |
| Asset Turnover: 68.24% > 50% (prev 59.42%; Δ 8.82% > 0%) |
| Interest Coverage Ratio: -9.95 > 6 (EBITDA TTM -32.5m / Interest Expense TTM 6.71m) |
Altman Z'' -0.49
| A: 0.67 (Total Current Assets 2.93b - Total Current Liabilities 558.0m) / Total Assets 3.57b |
| B: -0.54 (Retained Earnings -1.93b / Total Assets 3.57b) |
| C: -0.02 (EBIT TTM -66.8m / Avg Total Assets 3.40b) |
| D: -2.83 (Book Value of Equity -1.92b / Total Liabilities 678.2m) |
| Altman-Z'' Score: -0.49 = B |
Beneish M -2.68
| DSRI: 1.03 (Receivables 416.5m/334.6m, Revenue 2.32b/1.92b) |
| GMI: 1.03 (GM 71.62% / 73.72%) |
| AQI: 1.46 (AQ_t 0.16 / AQ_t-1 0.11) |
| SGI: 1.21 (Revenue 2.32b / 1.92b) |
| TATA: -0.13 (NI -70.9m - CFO 384.4m) / TA 3.57b) |
| Beneish M-Score: -2.68 (Cap -4..+1) = A |
What is the price of MDB shares?
Over the past week, the price has changed by -7.27%, over one month by -21.00%, over three months by -3.23% and over the past year by +23.82%.
Is MDB a buy, sell or hold?
- StrongBuy: 19
- Buy: 9
- Hold: 12
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MDB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 448.8 | 30.3% |
| Analysts Target Price | 448.8 | 30.3% |
| ValueRay Target Price | 345.1 | 0.2% |
MDB Fundamental Data Overview February 01, 2026
P/S = 13.1379
P/B = 10.5393
P/EG = 1.6716
Revenue TTM = 2.32b USD
EBIT TTM = -66.8m USD
EBITDA TTM = -32.5m USD
Long Term Debt = 34.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.14m USD (from shortTermDebt, last quarter)
Debt = 34.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -799.5m USD (from netDebt column, last quarter)
Enterprise Value = 28.17b USD (30.44b + Debt 34.6m - CCE 2.31b)
Interest Coverage Ratio = -9.95 (Ebit TTM -66.8m / Interest Expense TTM 6.71m)
EV/FCF = 79.44x (Enterprise Value 28.17b / FCF TTM 354.6m)
FCF Yield = 1.26% (FCF TTM 354.6m / Enterprise Value 28.17b)
FCF Margin = 15.30% (FCF TTM 354.6m / Revenue TTM 2.32b)
Net Margin = -3.06% (Net Income TTM -70.9m / Revenue TTM 2.32b)
Gross Margin = 71.62% ((Revenue TTM 2.32b - Cost of Revenue TTM 657.7m) / Revenue TTM)
Gross Margin QoQ = 71.48% (prev 71.01%)
Tobins Q-Ratio = 7.90 (Enterprise Value 28.17b / Total Assets 3.57b)
Interest Expense / Debt = 7.33% (Interest Expense 2.54m / Debt 34.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -52.7m (EBIT -66.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.25 (Total Current Assets 2.93b / Total Current Liabilities 558.0m)
Debt / Equity = 0.01 (Debt 34.6m / totalStockholderEquity, last quarter 2.89b)
Debt / EBITDA = 24.58 (negative EBITDA) (Net Debt -799.5m / EBITDA -32.5m)
Debt / FCF = -2.25 (Net Debt -799.5m / FCF TTM 354.6m)
Total Stockholder Equity = 2.91b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.09% (Net Income -70.9m / Total Assets 3.57b)
RoE = -2.43% (Net Income TTM -70.9m / Total Stockholder Equity 2.91b)
RoCE = -2.27% (EBIT -66.8m / Capital Employed (Equity 2.91b + L.T.Debt 34.6m))
RoIC = -1.81% (negative operating profit) (NOPAT -52.7m / Invested Capital 2.91b)
WACC = 12.09% (E(30.44b)/V(30.48b) * Re(12.10%) + D(34.6m)/V(30.48b) * Rd(7.33%) * (1-Tc(0.21)))
Discount Rate = 12.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.55%
[DCF Debug] Terminal Value 69.13% ; FCFF base≈271.9m ; Y1≈335.5m ; Y5≈571.3m
Fair Price DCF = 74.05 (EV 5.23b - Net Debt -799.5m = Equity 6.03b / Shares 81.4m; r=12.09% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 50.29 | EPS CAGR: -12.49% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.72 | Revenue CAGR: 25.70% | SUE: 3.78 | # QB: 16
EPS next Quarter (2026-04-30): EPS=1.20 | Chg30d=+0.001 | Revisions Net=+28 | Analysts=31
EPS next Year (2027-01-31): EPS=5.56 | Chg30d=+0.004 | Revisions Net=+1 | Growth EPS=+15.7% | Growth Revenue=+18.4%